Back to results

Milnacipran for Chronic Pain in Knee Osteoarthritis (KOA)

Primary Purpose

Knee Osteoarthritis, Degenerative Joint Disease, Chronic Pain

Status

Completed

Phase

Phase 4

Locations

Study Type

Interventional

Intervention

Milnacipran

Placebo

About this trial

This is an interventional treatment trial for Knee Osteoarthritis focused on measuring Knee Osteoarthritis, Degenerative Joint Disease, Chronic Pain, Knee Pain

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Knee pain and osteophytes on radiographs OR
Knee pain plus patient age of 40 years or older, morning stiffness lasting 30 minutes or less, and crepitus (cracking sound) during motion
Experiences chronic pain for 6 months or longer
Average pain rating of worse knee is equal to 4 or greater on a 0-10 scale
If female, is not pregnant or breast feeding, and not currently attempting to conceive; if of childbearing potential, use of a highly effective method of birth control (as determined by Pl)
Able to walk at least ½ a city block a day, and agrees to try and slowly increase that over the course of study
Able to read and speak English and provide informed consent
Able to understand and comply with all data collection methodology including electronic diary
Subject agrees to 1) continue their stable drug regimen with no changes during the course of study, 2) only use Tylenol 325 mg of tablets (a maximum of 8 tablets a day) for breakthrough pain, and 3) not use Tylenol or any other pain medicines 12 hours before testing.

Exclusion Criteria:

Subject takes SNRIs (Savella, Cymbalta, Venlafaxine) or other neuroamine re-uptake blockers for mood disorders
Subject is allergic to SSRIs, SNRIs, or milnacipran
Subject has severe or untreated psychiatric disturbance (e.g. mania, depression, anxiety, substance dependence)
Subject is medicated with 'triptans, MAOIs, SSRIs, other SNRIs, tricyclic or heterocyclic antidepressants, lithium, epinephrine, norepinephrine, clonidine or digoxin during the trial
Subject has a clinical diagnosis of fibromyalgia
Subject has severe ongoing or unaddressed medical conditions (e.g. Renal or Hepatic disease [creatinine>1.5 ml/dl; AST or ALT> 3x normal limit], uncontrolled hypertension, severe cardiac rate or rhythm disorders, rheumatologic disease (e.g. polymyalgia rheumatica), narrow angle glaucoma, hyponatremia, clotting disorders, uncontrolled seizure disorder or urinary retention)
Subject has cardiac implants
Subject has a knee replacement
Subject plans to start new pain treatments or therapies during the study (e.g. new pain medication, injections, PT, surgery)

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Sugar Pill

Milnacipran

Arm Description

BID placebo

Uptitration from 10mg to 50mg BID Milnacipran

Outcomes

Primary Outcome Measures

McGill Pain Questionnaire - Short Form

The MPQ-SF is a well-validated pain measure that permits separation of the sensory and affective components of pain, which are added together to compute a total score. The scale ranges from 0-45 (0=no pain, 45=the most pain).

PamSys Actigraph Data

We used a body worn sensor (PAMSys™, Biosensics, LLC, MA)(25-27) embedded in a comfortable t-shirt at the sternal level. Participants wore the PAMSys after the visit for 48 hours. The device provides values related to subjects spontaneous physical activity including percentage of time standing and walking. These variables provide different indexes of participants' level of activity and activity organization, and were reported by subjects with KOA pain as relevant.

Pain Anxiety Symptoms Scale (PASS)

Anxiety scores were collected at least two data points. The Pain Anxiety Symptoms Scale (PASS) is a scale from 0 - 100, where 0 = no anxiety and 100 = the most anxiety.

Pain Disability Index (PDI)

The PDI is a seven-item, validated instrument that assesses perceived disability in seven key life areas. It provides a total disability score, and is an indirect measure of self efficacy. The Pain Disability Scale is a scale from 0 - 70, where 0 = no Disability and 70 = the most Disability.

Center for Epidemiological Studies Depression Scale CESD-10 (CES-D 10)

The CES-D 10 is a 10-item questionnaire that has been validated for the assessment of depressive symptomatology. The Depression Scale is a scale with a sum score from 0 - 30, where 0 = no Depression and 30 = the most Depression.

Pain Visual Analogue Scale

Pain Visual Analogue Scale from 0-100 (0= no pain, and 100= most pain).

Secondary Outcome Measures

Daily Diary Entries With Pain, Fatigue and Functioning Scores Three Times a Day

Averages of daily diary outcomes were taken over the first and last week of the trial (week 1 and week 11) to compare pre and post treatment. diary was filled out 3 times a day and asked subjects to rate pain at rest, pain when walking, and fatigue on a scale 0-10 (0=none, and 10=the worst)

Full Information

NCT ID

NCT01510457

First Posted

November 29, 2011

Last Updated

May 26, 2015

Sponsor

Dr. Norman Harden

Collaborators

Forest Laboratories

1. Study Identification

Unique Protocol Identification Number

NCT01510457

Brief Title

Milnacipran for Chronic Pain in Knee Osteoarthritis

Acronym

KOA

Official Title

Milnacipran for the Pain, Sensory Sensitization and Mood Changes in Knee Osteoarthritis

Study Type

Interventional

2. Study Status

Record Verification Date

May 2015

Overall Recruitment Status

Completed

Study Start Date

November 2010 (undefined)

Primary Completion Date

October 2013 (Actual)

Study Completion Date

October 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

Dr. Norman Harden

Collaborators

Forest Laboratories

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The patients are asked to take part in this study because you have chronic pain as a result of knee osteoarthritis. This study is done to investigate the pain relieving effects of the study drug Savella (milnacipran HCl) for people who experience chronic osteoarthritis pain. The purpose of this research is to look at how the study drug can be used to benefit people who experience osteoarthritis knee pain. This is a phase IV study done to study the safety and effectiveness of the drug. At this point the drug is already approved by the Food and Drug Administration for people with fibromyalgia but it has not yet been approved for people with knee osteoarthritis.

Detailed Description

If you are in this study, you will be placed in one of two study groups: one group will receive the study drug and one will receive a placebo. You will be assigned a study group by chance using a process similar to the flip of a coin. At the first visit (week one) we will review and sign the informed consent, obtain your medical health history, and conduct a brief physical exam. You will also complete several questionnaires about your pain. You will be assessed for your eligibility to participate in this study. If you are eligible, we will conduct some physical and sensory tests and collect a blood sample. The physical tests include a stair climb, 6-minute treadmill test and a 1-minute sit to stand test. The sensory tests allow us to understand your perception of various stimuli such as vibration, light touch, pinprick, heat, cold, hot pain, and cold pain. At the end of the first visit you will be given an electronic diary to record your pain throughout the study. We will also ask you to wear a device in a T-shirt, similar to an accelerometer, that will be used to record your sleep quality and physical activity for 2 days. At the second (week two) and third visits (week nine) you will be asked to complete the same questionnaires, physical and sensory tests as during the first visit. You will also have to wear the t-shirt with the device for 2 days after each visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Knee Osteoarthritis, Degenerative Joint Disease, Chronic Pain

Keywords

Knee Osteoarthritis, Degenerative Joint Disease, Chronic Pain, Knee Pain

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 4

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

46 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Sugar Pill

Arm Type

Placebo Comparator

Arm Description

BID placebo

Arm Title

Milnacipran

Arm Type

Experimental

Arm Description

Uptitration from 10mg to 50mg BID Milnacipran

Intervention Type

Drug

Intervention Name(s)

Milnacipran

Other Intervention Name(s)

Savella (milnacipran HCL) Tablets

Intervention Description

Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.

Intervention Type

Drug

Intervention Name(s)

Placebo

Other Intervention Name(s)

"Sugar Pill"

Intervention Description

Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.

Primary Outcome Measure Information:

Title

McGill Pain Questionnaire - Short Form

Description

Time Frame

Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

Title

PamSys Actigraph Data

Description

Time Frame

48 hours after visit 3

Title

Pain Anxiety Symptoms Scale (PASS)

Description

Anxiety scores were collected at least two data points. The Pain Anxiety Symptoms Scale (PASS) is a scale from 0 - 100, where 0 = no anxiety and 100 = the most anxiety.

Time Frame

Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

Title

Pain Disability Index (PDI)

Description

Time Frame

Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

Title

Center for Epidemiological Studies Depression Scale CESD-10 (CES-D 10)

Description

Time Frame

Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

Title

Pain Visual Analogue Scale

Description

Pain Visual Analogue Scale from 0-100 (0= no pain, and 100= most pain).

Time Frame

Collected at 2 visits over 11 weeks: Visit 1 and Visit 3.

Secondary Outcome Measure Information:

Title

Daily Diary Entries With Pain, Fatigue and Functioning Scores Three Times a Day

Description

Time Frame

electronic diary entries with pain, fatigue and functioning scores were completed three times a day during week 1 and week 11

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

90 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Knee pain and osteophytes on radiographs OR Knee pain plus patient age of 40 years or older, morning stiffness lasting 30 minutes or less, and crepitus (cracking sound) during motion Experiences chronic pain for 6 months or longer Average pain rating of worse knee is equal to 4 or greater on a 0-10 scale If female, is not pregnant or breast feeding, and not currently attempting to conceive; if of childbearing potential, use of a highly effective method of birth control (as determined by Pl) Able to walk at least ½ a city block a day, and agrees to try and slowly increase that over the course of study Able to read and speak English and provide informed consent Able to understand and comply with all data collection methodology including electronic diary Subject agrees to 1) continue their stable drug regimen with no changes during the course of study, 2) only use Tylenol 325 mg of tablets (a maximum of 8 tablets a day) for breakthrough pain, and 3) not use Tylenol or any other pain medicines 12 hours before testing. Exclusion Criteria: Subject takes SNRIs (Savella, Cymbalta, Venlafaxine) or other neuroamine re-uptake blockers for mood disorders Subject is allergic to SSRIs, SNRIs, or milnacipran Subject has severe or untreated psychiatric disturbance (e.g. mania, depression, anxiety, substance dependence) Subject is medicated with 'triptans, MAOIs, SSRIs, other SNRIs, tricyclic or heterocyclic antidepressants, lithium, epinephrine, norepinephrine, clonidine or digoxin during the trial Subject has a clinical diagnosis of fibromyalgia Subject has severe ongoing or unaddressed medical conditions (e.g. Renal or Hepatic disease [creatinine>1.5 ml/dl; AST or ALT> 3x normal limit], uncontrolled hypertension, severe cardiac rate or rhythm disorders, rheumatologic disease (e.g. polymyalgia rheumatica), narrow angle glaucoma, hyponatremia, clotting disorders, uncontrolled seizure disorder or urinary retention) Subject has cardiac implants Subject has a knee replacement Subject plans to start new pain treatments or therapies during the study (e.g. new pain medication, injections, PT, surgery)

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Norman Harden, MD

Organizational Affiliation

Center for Pain Studies, Rehabilitation Institute of Chicago

Official's Role

Principal Investigator

12. IPD Sharing Statement

Citations:

PubMed Identifier

36269595

Citation

Leaney AA, Lyttle JR, Segan J, Urquhart DM, Cicuttini FM, Chou L, Wluka AE. Antidepressants for hip and knee osteoarthritis. Cochrane Database Syst Rev. 2022 Oct 21;10(10):CD012157. doi: 10.1002/14651858.CD012157.pub2.

Results Reference

derived

Learn more about this trial

Milnacipran for Chronic Pain in Knee Osteoarthritis

We'll reach out to this number within 24 hrs